| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 64,380 | 57,420 | 51,350 | 55,310 | 71,860 |
| Sales Growth | +12.12% | +11.82% | -7.16% | -23.03% | -2.11% |
| Net Income | -56,420 | -55,190 | 872,130 | -199,430 | -278,020 |
| Net Income Growth | -2.23% | -106.33% | +537.31% | +28.27% | -17.58% |
Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 - Innoviva, Inc. (then Theravance, Inc.) and Theravance.'
Fiscal Year End Date: 12/31